Small Lymphocytic Lymphoma
📧 Sign up to get email alerts when something new happens for Small Lymphocytic Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2019-04-16Clinical Trial Update: A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) [Phase 3]
Phase 3 trial comparing ibrutinib+obinutuzumab vs chlorambucil+obinutuzumab in treatment-naïve CLL/SLL; study completed with results posted …
-
CLINICAL_TRIALS trial_result · 2019-02-26Clinical Trial Update: Dose Optimization Trial of CD19 Redirected Autologous T Cells [Phase 2]
Phase 2 dose optimization trial of CD19 redirected autologous T cells in adults with relapsed/refractory CLL or SLL has completed with poste…
-
CLINICAL_TRIALS research · 2019-02-01Clinical Trial Update: A Phase I Study of AC0010 in Patients With CLL/ SLL, MCL, DLBCL and Other NHL [Phase 1]
Phase I trial evaluating AC0010 in patients with CLL/SLL, mantle cell lymphoma, diffuse large B-cell lymphoma, and other non-Hodgkin lymphom…
-
CLINICAL_TRIALS trial_result · 2019-01-23Clinical Trial Update: Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) [Phase 2]
Phase 2 study evaluating novel approaches to prevent graft-versus-host disease after allogeneic hematopoietic cell transplantation, with res…
-
CLINICAL_TRIALS trial_result · 2019-01-08Clinical Trial Update: A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO) [Phase 3]
Phase 3 trial comparing duvelisib to ofatumumab in relapsed/refractory CLL/SLL has completed with results posted.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2018-09-18Clinical Trial Update: Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 2]
Phase 2 trial investigating ofatumumab, pentostatin, and cyclophosphamide for untreated chronic lymphocytic leukemia or small lymphocytic ly…
-
CLINICAL_TRIALS trial_result · 2018-07-11Clinical Trial Update: PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 2]
Phase 2 clinical trial update of the BTK inhibitor Ibrutinib (PCI-32765) in special cases of chronic lymphocytic leukemia and small lymphocy…
-
CLINICAL_TRIALS trial_result · 2018-07-02Clinical Trial Update: CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma [Phase 1]
Phase 1 trial evaluating a triple regimen of devimistat (CPI-613), bendamustine hydrochloride, and rituximab in relapsed or refractory B-cel…
-
CLINICAL_TRIALS trial_result · 2018-04-23Clinical Trial Update: Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma [Phase 1]
Phase 1 study evaluating the combination of bortezomib and romidepsin in patients with chronic lymphocytic leukemia or small lymphocytic lym…
-
CLINICAL_TRIALS trial_result · 2018-04-12Clinical Trial Update: Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers [Phase 3]
Phase 3 trial update on the efficacy and safety of ibrutinib in patients with chronic lymphocytic leukemia and indolent B-cell lymphomas who…
-
CLINICAL_TRIALS trial_result · 2018-03-30Clinical Trial Update: BR in Patients With CLL With Comorbidities and/or Renal Dysfunction [Phase 1]
A Phase 1 clinical trial evaluating the bendamustine-rituximab (BR) regimen in patients with chronic lymphocytic leukemia or small lymphocyt…
-
CLINICAL_TRIALS trial_result · 2018-03-22Clinical Trial Update: Retrospective Study: Efficacy and Safety of Chlorambucil + Rituximab in CLL Patients
A retrospective study evaluated the efficacy and safety of chlorambucil plus rituximab in chronic lymphocytic leukemia patients.
-
CLINICAL_TRIALS trial_result · 2018-03-15Clinical Trial Update: Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia [Phase 1, Phase 2]
This clinical trial update reports completed Phase 1/Phase 2 studies evaluating the combination of ofatumumab and dinaciclib in patients wit…
-
CLINICAL_TRIALS trial_result · 2018-02-08Clinical Trial Update: Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating a Vorinostat-containing regimen (vorinostat, fludarabine phosphate, cyclophosphamide, and rituximab) i…
-
FDA approval · 2018-02-06FDA Approved: ZYDELIG — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for ZYDELIG (idelalisib) filed by Gilead Sciences, Inc.
-
FDA approval · 2018-01-26FDA Approved: ZYDELIG — Supplemental Application (Gilead Sciences, Inc.)
FDA approved a supplemental application for ZYDELIG (idelalisib) by Gilead Sciences, Inc.
-
CLINICAL_TRIALS trial_result · 2017-12-08Clinical Trial Update: Fludarabine Phosphate and Total-Body Irradiation Before Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia [Phase 2]
Phase 2 trial evaluating fludarabine phosphate with total-body irradiation as conditioning before donor peripheral blood stem cell transplan…
-
CLINICAL_TRIALS trial_result · 2017-12-07Clinical Trial Update: Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating autologous stem cell transplant followed by donor stem cell transplant in relapsed or refractory lymphom…
-
CLINICAL_TRIALS withdrawal · 2017-12-02Clinical Trial Update: T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies [Phase 1, Phase 2]
A trial investigating T-regulatory cell and CD3-depleted double umbilical cord blood transplantation for hematologic malignancies has been w…
-
CLINICAL_TRIALS trial_result · 2017-10-12Clinical Trial Update: Tositumomab and Iodine I 131 Tositumomab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in First Remission [Phase 2]
This clinical trial update reports Phase 2 results for tositumomab in combination with iodine-131 for treating chronic lymphocytic leukemia …
-
CLINICAL_TRIALS trial_result · 2017-10-09Clinical Trial Update: Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma [Phase 2]
Phase 2 clinical trial evaluating the combination of pegfilgrastim and rituximab in patients with untreated, relapsed, or refractory follicu…
-
CLINICAL_TRIALS trial_result · 2017-09-29Clinical Trial Update: A Phase I/II Study of Intratumoral Injection of SD-101 [Phase 1, Phase 2]
Phase I/II trial investigating intratumoral SD-101 for various B-cell lymphomas; study completed with results posted in 2017.
-
CLINICAL_TRIALS trial_result · 2017-07-17Clinical Trial Update: First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance. [Phase 3]
A Phase 3 trial comparing first-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphomas with maintenance therapy; the s…
-
CLINICAL_TRIALS trial_result · 2017-07-13Clinical Trial Update: Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL [Phase 2]
Phase 2 trial evaluating bendamustine/rituxan induction chemotherapy followed by Revlimid maintenance in relapsed/refractory chronic lymphoc…
-
FDA approval · 2017-06-22FDA Approved: RITUXAN HYCELA — Original Application (Genentech, Inc.)
FDA approved RITUXAN HYCELA (rituximab and hyaluronidase) under an Original Application by Genentech. The subcutaneous formulation provides …